Characterization of Immunosuppressive Signing of Cervical Cancer (Xac03)

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Not yet enrolling

Conditions: Cervical Cancer

Treatments: Biological: Blood sample

Study type: Interventional

Funder types: Other

Identifiers

NCT02875990

2014-03

2015-A00699-40 (Registry Identifier)

Details and patient eligibility

About

Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T cell response Such mechanisms would promote progression to cancer and progression of it . Various factors such as an increase of regulatory T cells, the presence of myeloid cells and suppressor of defects in the signaling pathway Toll Like Receptor (TLR) may have a key role in these immunosuppression mechanisms. At this stage of knowledge, a better characterization of local and systemic immunosuppressive signing of cervical cancer is needed. The results should have a significant medical impact for the identification of new prognostic markers and new therapeutic targets for the treatment of patients with cervical cancer.

The aim of this research project is to define the signing of immunosuppressive cancer cervix and analyze the different mechanisms involved in this immunosuppression.

Enrollment: 50 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The women presenting for initial therapeutic management of cervical cancer
• Elderly patients over 18 years
• Patients beneficiary of a social security scheme
• Pregnant women can not participate in this study
• Women known to be HIV positive will not participate in this study

Exclusion criteria

• Patients with a recurrence of a treaty cervical cancer
• Patients with a history of pelvic radiotherapy
• Patients unable to receive informed about the progress and objectives of the study
• Patients not receiving a social security scheme
• Patients who have not signed informed consent
• Immunocompromised patients and pregnant women

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

patients with invasive cervical cancer

Experimental group

Description:

Blood sample

Treatment:

Biological: Blood sample